Current and future developments in the use of temozolomide for the treatment of brain tumours

Roger Stupp*, Marc Gander, Serge Leyvraz, Edward Newlands

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

208 Scopus citations


Brain tumours comprise only 2% of all adult cancers, but they are among the most debilitating malignant diseases. Temozolomide, an alkylating agent that can be administered orally, has been approved for the treatment of recurrent malignant glioma on a daily schedule for 5-day cycles. Continuous administration schedules with a higher dose intensity are being explored, but an improvement in efficiency remains to be shown. The benefit from temozolomide given as a single agent in recurrent disease will be several weeks at best. This drug is therefore now undergoing clinical testing as neoadjuvant chemotherapy or with concomitant radiotherapy in patients with newly diagnosed glioma. Several phase I trials are investigating the combination of temozolomide with other agents active against brain tumours. This review briefly summarises the pharmacological background and clinical development of temozolomide and focuses on current and future clinical exploration of this drug for the treatment of brain tumours.

Original languageEnglish (US)
Pages (from-to)552-560
Number of pages9
JournalLancet Oncology
Issue number9
StatePublished - Sep 1 2001

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Current and future developments in the use of temozolomide for the treatment of brain tumours'. Together they form a unique fingerprint.

Cite this